Table 1 (abstract P57). Clinical and laboratory data of the study population

Gender, n (%)

Symptoms at presentation, n (%)

SARS-CoV2 serologic status, n (%)

Hemoglobin

12.2 g/dL

(9.4 – 15.5)

ALT

24 U/L

(8 – 115)

 Male

14 (52)

Fever

26 (96.3)

IgG+ / IgM-

24 (88.9)

Platelet count

197 10³/μL (62 – 513)

LDH

540 U/L

(317 – 1014)

 Female

13 (48)

Abdominal pain

16 (59.2)

IgG+ / IgM+

2 (7.4)

CRP

112.3 mg/L (9.15 – 420.8)

Albumin

3.4 g/dL

(2.1 – 4.5)

Age, yrs

7.1

(0.8-12.3)

Diarrhea

14 (51.8)

IgG- / IgM+

1 (3.7)

PCT

2.38 ng/mL (0.16 – 188)

Triglycerides

193mg/dL

(70 - 850)

History of SARS-CoV2

infection/contact, n (%)

Vomit

12 (44.4)

Blood tests

Fibrinogen

598 mg/dL (223 – 1109)

Creatinin

0.43 mg/dL

(0.15 – 1.63)

 Previous infection

5 (18.5)

Conjunctivitis

13 (48.1)

WBC count

11.74 10³/μL

(4.16 – 28.72)

D-dimer

1016 ng/ml (8.8 - 14776)

CK

80 U/L

(16 - 5930)

 Close contact with SARS-CoV2+ subject

9 (33.3)

Skin rash

11 (40.7)

Neutrophil count

9.41 10³/μL

(3.29 – 24.64)

Ferritin

635.8 μg/L (31.3 – 8115)

BNP

199.5 pg/mL

(5 - 5000)

 Both

8 (29.6)

Other

0 (0)

Lymphocyte count

1.29 10³/μL

(0.36 – 15.93)

AST

31 U/L

(13 – 245)

Troponin

25.2 ng/L

(0.02 - 1523)